Free Trial

Laura Sutcliffe Analyst Performance

Analyst at Citigroup

Laura Sutcliffe is a stock analyst at Citigroup in the medical sector, covering 6 publicly traded companies. Over the past year, Laura Sutcliffe has issued 5 stock ratings, including strong buy and buy recommendations. While full access to Laura Sutcliffe's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Sutcliffe's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 9 Years
Buy Recommendations
85.71% 12 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy7.1%1 ratings
Buy78.6%11 ratings
Hold14.3%2 ratings
Sell0.0%0 ratings

Out of 14 total stock ratings issued by Laura Sutcliffe at Citigroup, the majority (78.6%) have been Buy recommendations, followed by 14.3% Hold and 7.1% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
50.0% of companies on NASDAQ
3 companies
NYSE
33.3% of companies on NYSE
2 companies
OTCMKTS
16.7% of companies on OTCMKTS
1 company

Laura Sutcliffe, an analyst at Citigroup, currently covers 6 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Laura Sutcliffe of Citigroup specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
66.7%
MED PRODUCTS
1 company
16.7%
PHARMACEUTICAL PREPARATIONS
1 company
16.7%

Laura Sutcliffe's Ratings History at Citigroup

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
ResMed Inc. stock logo
RMD
ResMed
9/18/2025Initiated Coverage$271.91$330.00Buy
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
9/18/2025Initiated Coverage$9.38$22.00Buy
ResMed Inc. stock logo
RMD
ResMed
9/16/2025Upgrade$273.45Strong-Buy
ResMed Inc. stock logo
RMD
ResMed
8/1/2025Boost Price Target$279.57$325.00Buy
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1/27/2025Boost Price Target$18.60$22.00Buy